Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer-Reference-Cited by-同舟云学术

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer

Published:2018-04-02 Issue:6 Volume:18 Page:531-541
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Stebbing Justin¹,Baranau Yauheni²,Manikhas Alexey³,Lee Sang Joon⁴,Thiruchelvam Paul¹,Leff Daniel¹,Esteva Francisco J.⁵

Affiliation:

1. Division of Surgery and Cancer, Imperial College, Imperial College Healthcare NHS Trust, London, UK

2. Chemotherapy Department #1, Minsk City Clinical Oncological Dispensary, Minsk, Belarus

3. Breast Cancer Department, City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation

4. Clinical Development Division, CELLTRION Inc, Incheon, Republic of Korea

5. Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA

Funder

Celltrion Healthcare Co., Ltd

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2018.1457442

Reference80 articles.

1. Pathologic Changes in Breast Cancer Following Neoadjuvant Chemotherapy: Implications for the Assessment of Response

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

3. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

4. Can Early Response Assessment Guide Neoadjuvant Chemotherapy in Early-Stage Breast Cancer?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;British Journal of Cancer;2024-06-21

2. Successful treatment of enormous locally advanced breast cancer through neoadjuvant chemotherapy and surgical intervention: a case report;Gland Surgery;2024-06

3. Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis;Technology in Cancer Research & Treatment;2023-01

4. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting;JAMA Oncology;2022-05-01

5. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars;Journal of Clinical Oncology;2020-04-01